International Centre For Genetic Engineering And Biotechnology (ICGEB)
SKU:
153794
Product description:
This minigene construct consists of a minimal alpha globin promoter and SV40 enhancer which drive the transcription of the minigene. Downstream, an alpha-globin-fibronectin EDB minigene is present with a unique NdeI site where a fragment that contains exon 9 (183bp) along with part of the flanking introns was inserted. The exon 9 sequence also carries a C155T mutation that destroys a splicing enhancer within its sequence. This means that when transfected into cells the exon 9 is included approximately in 50% of the transcripts. In this manner, it is possible to see changes both with regards to upregulation of exon inclusion or its downregulation. Concentration 2ug/ml
This minigene construct consists of a minimal alpha globin promoter and SV40 enhancer which drive the transcription of the minigene. Downstream, an alpha-globin-fibronectin EDB minigene is present with a unique NdeI site where a fragment that contains exon 9 (183bp) along with part of the flanking introns was inserted. The exon 9 sequence also carries a C155T mutation that destroys a splicing enhancer within its sequence. This means that when transfected into cells the exon 9 is included approximately in 50% of the transcripts. In this manner, it is possible to see changes both with regards to upregulation of exon inclusion or its downregulation.
Cat. #:
153794
Tool sub type:
pBluescript KS
Research Fields:
Genetics
Target:
CFTR Exon 9 minigene
Backbone size without insert:
2958
Bacterial resistance:
Ampicillin
Application notes:
Concentration 2ug/ml
References:
D'Ambrogio et al. 2009. Nucleic Acids Res. 37(12):4116-26. PMID: 19429692.
Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo.
Pagani et al. 2003. J Biol Chem. 278(29):26580-8. PMID: 12732620.
Missense, nonsense, and neutral mutations define juxtaposed regulatory elements of splicing in cystic fibrosis transmembrane regulator exon 9.
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.
